MedTrace Logo

MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia

NCT07371403 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-03-25

No results posted yet for this study

Summary

Single-arm, prospective, open-label feasibility study evaluating the technical and operational feasibility of manufacturing autologous CD19-directed CAR-T cells (MB-CART19.1) at the point of care for the treatment of relapsed or refractory B-ALL in pediatric and adult patients.

Conditions

  • Acute Lymphoblastic Leukemia
  • Acute Lymphoblastic Leukemia Recurrent
  • Acute Lymphoblastic Leukemia Refractory
  • Acute Lymphoblastic Leukemia Not Having Achieved Remission
  • Acute Lymphoblastic Leukemia With Failed Remission

Interventions

GENETIC

MB-CART19.1

All participants will undergo leukapheresis for collection of autologous T cells, which will then be manufactured into MB-CART19.1 on-site using CliniMACS Prodigy platform. Successfully manufactured MB-CART19.1 products will be infused back to the patient following a lymphodepleting chemotherapy regimen.

Sponsors & Collaborators

  • King Hussein Cancer Center

    lead OTHER

Principal Investigators

  • Dr Zaid Abdel Rahman, Consultant,Hematology/Oncology · King Hussein Cancer Center

  • Dr. Hasan Hashem, Consultant,Hematology/Oncology · King Hussein Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-28
Primary Completion
2029-01-31
Completion
2029-01-31

Countries

  • Jordan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07371403 on ClinicalTrials.gov